Tioguanine
- Generic Name
- Tioguanine
- Brand Names
- Lanvis, Tabloid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N5S
- CAS Number
- 154-42-7
- Unique Ingredient Identifier
- WIX31ZPX66
- Background
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
- Indication
For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
- Associated Conditions
- Acute Non-Lymphocytic Leukemia, Nonlymphocytic Acute myeloid leukemia
- Associated Therapies
- -
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: RuxolitinibDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: VincristineDrug: PegaspargaseDrug: RituximabDrug: Methotrexate (Intrathecal Administration)Drug: Methotrexate (Intravenous Administration)Drug: DexamethasoneDrug: DoxorubicinDrug: ThioguanineDrug: Methotrexate Oral Product
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AllopurinolDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: Vincristine SulfateDrug: DexamethasoneDrug: Pegylated L-AsparaginaseDrug: MethotrexateProcedure: Bone Marrow Aspiration and BiopsyDrug: CyclophosphamideDrug: MercaptopurineBiological: RituximabDrug: ThioguanineDrug: DoxorubicinOther: Laboratory Biomarker AnalysisBiological: Inotuzumab Ozogamicin
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 310
- Registration Number
- NCT03150693
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase PegolProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Dexrazoxane HydrochlorideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideDrug: Imatinib MesylateDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: PegaspargaseDrug: PrednisoloneDrug: MercaptopurineDrug: MethylprednisoloneOther: Questionnaire AdministrationDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Conditions
- Interventions
- Drug: AzacitidineDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Hydrocortisone Sodium SuccinateOther: Laboratory Biomarker AnalysisDrug: LeucovorinDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoloneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02828358
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02660762
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 280
- Registration Number
- NCT02521493
- Locations
- 🇨🇦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇳🇿Christchurch Hospital, Christchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.